Unfortunately our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D, and a very-very strong balance sheet with huge value drivers at the end of it.

I have a great team who has helped me build Biocon, I was very fortunate to be able to share my vision with a group of people who really were as excited about challenges as I was.

I faced a number of challenges whilst I built Biocon. Initially, I had credibility challenges where I couldn't get banks to fund me; I couldn't recruit people to work for a woman boss. Even in the businesses where I had to procure raw materials, they didn't want to deal with women.

It was a chance encounter with a biotech entrepreneur from Ireland that got me started as an entrepreneur in India, because I partnered this Irish company in setting up India's first biotech company.

As a traditionally risk-averse nation, India has rarely been at the forefront of innovation. Indian companies have mostly imitated others and became very good at it.

My legacy is going to be in affordable health care. I am willing to invest in developing that model and the policies around it.

Unfortunately our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D, and a very-very strong balance sheet with huge value drivers at the end of it.